Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
Clinical trial NCT07462455 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07462455
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-31
- Primary completion
- 2027-02-28
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.